Skip to content

Released Nov 8, 2022, after the close

10-Q filed Nov 8, 2022, 39 days after period end · 0000950170-22-023279

Q3 2022 · 10-Q
Revenue$25.15M+195.3% vs Q3 2021−10.5% vs Q2 2022
Net Income-$19.49MN/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.37N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$21,210,000N/M
Operating Cash Flowderived$65,854,000N/M
Margins · derived
Operating margin-84.3%+322.8 pt vs Q3 2021
Net margin-77.5%+285.3 pt vs Q3 2021

What the release said

The release

Same quarter

MetricQ3 2022Q3 2021Q3 2020Q3 2019
Revenue$25.15M$8.52M$17.82M$12.28M
Net Income-$19.49M-$30.90M$17.14M-$12.91M
EPS Diluted-$0.37-$0.67$0.45-$0.56

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR